Bausch + Lomb (NYSE:BLCO) Price Target Increased to $15.50 by Analysts at Evercore ISI

Bausch + Lomb (NYSE:BLCO - Get Free Report) had its price objective raised by Evercore ISI from $15.00 to $15.50 in a research report issued to clients and investors on Tuesday, Benzinga reports. The firm currently has an "in-line" rating on the stock. Evercore ISI's price objective indicates a potential upside of 5.69% from the company's previous close.

Several other equities research analysts also recently commented on the stock. Needham & Company LLC reissued a "hold" rating on shares of Bausch + Lomb in a research report on Wednesday, May 1st. HC Wainwright reissued a "buy" rating and set a $20.00 target price on shares of Bausch + Lomb in a research report on Thursday, May 2nd. Evercore decreased their target price on shares of Bausch + Lomb from $17.00 to $15.00 and set an "in-line" rating for the company in a research report on Thursday, May 2nd. Royal Bank of Canada cut their price target on shares of Bausch + Lomb from $20.00 to $18.00 and set an "outperform" rating on the stock in a report on Monday, April 22nd. Finally, Morgan Stanley upgraded shares of Bausch + Lomb from an "equal weight" rating to an "overweight" rating and boosted their price target for the stock from $16.00 to $18.00 in a report on Monday, May 6th. Five research analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $19.32.

Bausch + Lomb Stock Up 0.5 %

BLCO traded up $0.07 during midday trading on Tuesday, hitting $14.67. The company had a trading volume of 333,379 shares, compared to its average volume of 455,610. Bausch + Lomb has a 52 week low of $13.16 and a 52 week high of $21.23. The company has a quick ratio of 1.03, a current ratio of 1.70 and a debt-to-equity ratio of 0.68. The company has a market capitalization of $5.16 billion, a price-to-earnings ratio of -15.28, a PEG ratio of 1.47 and a beta of 0.48. The stock's 50 day moving average price is $14.88 and its 200 day moving average price is $15.33.

Bausch + Lomb (NYSE:BLCO - Get Free Report) last posted its earnings results on Wednesday, May 1st. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.02). The business had revenue of $1.10 billion for the quarter, compared to the consensus estimate of $1.06 billion. Bausch + Lomb had a positive return on equity of 3.60% and a negative net margin of 7.81%. The company's revenue was up 18.0% on a year-over-year basis. During the same period in the previous year, the firm earned $0.10 earnings per share. On average, research analysts anticipate that Bausch + Lomb will post 0.64 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. River Road Asset Management LLC boosted its stake in Bausch + Lomb by 21.6% in the fourth quarter. River Road Asset Management LLC now owns 1,938,207 shares of the company's stock valued at $33,066,000 after acquiring an additional 343,772 shares during the last quarter. Freshford Capital Management LLC lifted its stake in shares of Bausch + Lomb by 29.8% during the 4th quarter. Freshford Capital Management LLC now owns 1,754,123 shares of the company's stock valued at $29,925,000 after buying an additional 403,062 shares in the last quarter. Whitebox Advisors LLC lifted its stake in shares of Bausch + Lomb by 29.3% during the 1st quarter. Whitebox Advisors LLC now owns 1,206,303 shares of the company's stock valued at $20,869,000 after buying an additional 273,484 shares in the last quarter. Invenomic Capital Management LP purchased a new stake in shares of Bausch + Lomb during the 1st quarter valued at approximately $6,817,000. Finally, Rokos Capital Management LLP bought a new stake in Bausch + Lomb during the 1st quarter worth approximately $5,602,000. 11.07% of the stock is currently owned by hedge funds and other institutional investors.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.